Private Equity
Location
Rotterdam, The Netherlands
Boston, MA, USA
Private Equity
All Portfolio items
See full Private Equity portfolio
Viroclinics Biosciences is a leader in diagnostic and clinical-trial services. It is one of the few labs in the world able to perform highly complex, specialized diagnostic and preclinical studies in the field of virology. Viroclinics operates globally as the preferred virology testing laboratory for top-ten biopharmaceutical companies.
Gilde acquired a majority share in 2013. During Gilde ownership Viroclinics developed new services for the biopharmaceutical industry, expanded its facilities and tripled its revenues. Viroclinics was sold in 2017 to Parcom Capital.
More Viroclinics Biosciences news
d3 Medicine LLC and Viroclinics Biosciences BV form virology drug development alliance to serve the
Gilde Healthcare Services acquires majority share in Viroclinics Biosciences from Erasmus MC
Synexa Life Sciences
Synexa Life Sciences is an industry leader in contract bioanalytics and biomarker research services specializing...
Detax
DETAX is a leading global supplier of biocompatible silicones and light-curing 3D resins for medical...
Chr. Diener / Koscher & Würtz
With the acquisition of Chr. Diener in 2022 and Koscher & Würtz (K&W) in 2023,...
